FRANKLIN, Tenn., July 24, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced its participation in the following investor conferences: CFO, Peter Kuipers, will participate in a fireside chat presentation at the 2024 KeyBanc Technology Leadership Forum on Tuesday, August 6, 2024, at 3:00 p.m. Eastern Time.CEO, An ...

FRANKLIN, Tenn., July 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will report second quarter 2024 financial results after market close on Monday, August 5, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on August 5, 2024, to discuss Clover Health’s business and financial results. Sec ...

FRANKLIN, Tenn., June 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it has received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). As previously disclosed ...

FRANKLIN, Tenn., June 14, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that the Centers for Medicare and Medicaid Services (“CMS”) has recalculated the 2024 Star Ratings of Clover Health’s PPO Medicare Advantage (“MA”) plans for the 2025 payment year, and has increased the rating by 0.5 Stars, to a revise ...

adventtr/iStock via Getty Images Clover Health Investments, Corp. (NASDAQ:CLOV) has recently announced that it will make its technology platform available for all Medicare Advantage payors and providers. This endeavor will effectively change the company’s business model from a traditional Medicare Advantage plan provider to a hybrid SaaS and shared-savings model, with options for full capitation. By doing so, Clover Health is finally embracing the AI aspect of its business model which could help boost its v ...

财务数据和关键指标变化 - 公司在第一季度实现了正的调整后EBITDA,达到700万美元,并有信心在2024年全年实现调整后EBITDA盈利,因此大幅提高了全年调整后EBITDA指引至1000万美元至3000万美元之间 [8][13] - 保险业务收入同比增长8%,达到3.42亿美元,并提高了全年保险业务收入指引至13亿美元至13.5亿美元之间 [9][14][15] - 医疗费用率(MCR)从去年同期的86.6%改善至77.9%,主要得益于优化运营、提高理赔和风险调整的准确性,以及从2023年良好表现中获得的有利基期发展 [40][41] 各条业务线数据和关键指标变化 - 公司正在投资于提高医疗质量的技术和服务,以及针对会员的临床奖励,这些成本目前计入销售及一般管理费用(SG&A),未来公司将披露一个新的"福利费用率"(BER)指标,预计全年将在低到中80%区间 [26][27] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司认为其独特的以技术为中心的医疗管理平台(Clover Assistant和Clover Home Care)使其在行业变革中处于有利地位,如HCC V28编码规则变化和医疗保险改革法案(IRA)的Part D变化 [52][53][54] - 公司正在调整运营架构,成立一个附属实体来统一公司的非临床质量改善服务,以提高新泽西州会员的医疗质量,并未来向第三方提供服务 [56][57] - 公司计划在2025年保持谨慎的计划设计,并专注于通过持续的SG&A优化来实现高单位数的收入增长 [60][61][62] 管理层对经营环境和未来前景的评论 - 公司认为其独特的技术驱动的医疗管理模式使其能够在行业变革中保持领先地位,如HCC V28编码规则变化和IRA的Part D变化 [52][53][54] - 公司有信心在2024年全年实现调整后EBITDA盈利,并有足够的资金满足运营和增长需求,因此授权了最高20亿美元的股票回购计划 [9][10] 问答环节重要的提问和回答 问题1 **Richard Close 提问** 询问公司2024年调整后EBITDA的季度走势,特别是涉及到变更医疗公司(Change Healthcare)黑客攻击和其他因素的影响 [65] **Andrew Toy 回答** 公司2023年的基期发展良好,给2024年的预测带来信心,但由于变更医疗公司的影响和内部系统过渡,导致第一季度有较高的IBNR准备,预计会在未来几个季度逐步消化 [66][67] 问题2 **Richard Close 提问** 询问公司是否会提供新的"福利费用率"(BER)指标的历史季度数据 [69] **Andrew Toy 回答** 公司计划在下个季度开始提供BER指标,并会提供一些历史数据以便比较 [70][71]

Clover Health Investments, Corp. (CLOV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 28.57%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.12, delivering a surprise of 33.33%. Over the last four quarters, the c ...

Clover Health Business Update & First Quarter 2024 Earnings Results Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including, without limitation, statements regarding future events and Clover Health Investments, Corp.’s (“Clover Health,” “we,” “our,” or “us”) expectations regarding positive Adjusted EBITDA and Adjusted SG&A (non-GAAP measures, as defined herein), targeted revenue and MCRs, future unregulated pro forma liquidity and cash, future result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39252 _________________________ ...

Clover Health Reports Strong First Quarter 2024 Financial Results; Improves Guidance to Target Full-Year 2024 Adjusted EBITDA Profitability First Quarter 2024 Insurance Revenue growth of 8% year-over-year First Quarter 2024 GAAP Net Loss from Continuing Operations of $23.2 million versus First Quarter 2023 loss of $79.7 million First Quarter Adjusted EBITDA profitability of $6.8 million versus prior period loss of $37.5 million Improves 2024 guidance to Insurance Revenue of $1.30 billion - $1.35 billion and ...